TABLE 2.
Country | Year | Vaccine type | SIA type | Extent of SIA | Target age group | Target population | Administrative coverage (%) |
---|---|---|---|---|---|---|---|
Bangladesh | 2005 | M | Catch-up | Pilot | 9 mos–10 yrs | 1,481,321 | 93 |
2006 | M | Catch-up | National | 9 mos–10 yrs | 34,199,590 | >100§ | |
2010 | M | Follow-up | National | 9 mos–5 yrs | 18,136,066 | 100 | |
Bhutan | 2006 | MR | Catch-up | National | 9 mos–14 yrs (males) and 15–44 yrs (females) | 338,040 | 98 |
North Korea | 2007 | M | Catch-up | National | 6 mos–45 yrs | 16,123,376 | 100 |
India | 2010 | M | Catch-up | Subnational | 9 mos–10 yrs | 10,469,901 | 90 |
2011 | M | Catch-up | Subnational | 9 mos–10 yrs | 34,127,013 | 90 | |
2012 | M | Catch-up | Subnational | 9 mos–10 yrs | 50,134,186 | 90 | |
2013 | M | Catch-up | Subnational | 9 mos–10 yrs | 36,012,805 | 93 | |
Indonesia | 2003 | M | Catch-up | Subnational | 6–12 yrs | 1,030,445 | 95 |
2004 | M | Catch-up | Subnational | 6–12 yrs | 2,180,918 | 94 | |
2005 | M | Catch-up | Subnational | 6 mos–15 yrs | 5,515,324 | 94 | |
2006 | M | Catch-up | Subnational | 6–12 yrs | 3,161,323 | 96 | |
2006 | M | Catch-up | Subnational | 6 mos–5 yrs | 3,978,096 | 93 | |
2007 | M | Follow-up | Subnational | 6 mos–5 yrs | 14,913,092 | 91 | |
2007 | M | Catch-up | Subnational | 6 mos–12 yrs | 5,473,025 | >100§ | |
2008 | M | Follow-up | Subnational | 1–3 yrs | 11,203 | 78 | |
2009 | M | Follow-up | Subnational | 9 mos–5 yrs | 2,124,572 | 92 | |
2010 | M | Follow-up | Subnational | 9 mos–5 yrs | 3,619,024 | 91 | |
2011 | M | Follow-up | Subnational | 9 mos–5 yrs | 11,989,559 | 95 | |
Maldives | 2005 | MR | Catch-up | National | 6–25 yrs (males) and 6–35 yrs (females) | 144,997 | 85 |
2006 | MR | Catch-up | National | 6–25 yrs (males) and 6–35 yrs (females) | 144,997 | 85 | |
2007 | MMR | Catch-up | National | 4–6 yrs | 29,529 | 56 | |
Myanmar | 2003 | M | Follow-up | National | 9 mos–5 yrs | 2,502,969 | 90 |
2004 | M | Follow-up | National | 9 mos–5 yrs | 1,679,487 | 65 | |
2007 | M | Follow-up | National | 9 mos–5 yrs | 6,056,000 | 94 | |
2012 | M | Follow-up | National | 9 mos–5 yrs | 6,432,064 | 97 | |
Nepal | 2004 | M | Catch-up | National | 9 mos–15 yrs | 5,344,765 | >100§ |
2005 | M | Catch-up | National | 9 mos–15 yrs | 4,326,348 | >100§ | |
2008 | M | Follow-up | National | 9 mos–59 mos | 199,751 | 97 | |
2008 | M | Follow-up | National | 9 mos–59 mos | 3,903,515 | 93 | |
2012 | MR | Catch-up | National | 9 mos–14 yrs | 9,579,306 | >100§ | |
Sri Lanka | 2003 | M | Catch-up | National | 10–15 yrs | 1,987,847 | 95 |
2004 | MR | Catch-up | National | 16–20 yrs | 1,890,326 | 72 | |
2013 | M | Catch-up | National | 6 mos–12m | 176,587 | 98 | |
Timor-Leste | 2003 | M | Catch-up | National | 9 mos–5 yrs | 128,318 | 99 |
2006 | M | Catch-up | National | 6 mos–14 yrs | 390,687 | 40 | |
2009 | M | Follow-up | National | 9 mos–5 yrs | 167,136 | 76 | |
2011 | M | Catch-up | National | 6 mos–14 yrs | 494,427 | 92 | |
Total | 300,597,935 |
Abbreviations: MCV = measles-containing vaccine; M = measles; MR = measles-rubella; MMR = measles-mumps-rubella.
SIAs generally are carried out using two target age ranges. An initial, nationwide catch-up SIA targets all children aged 9 months–14 years, with the goal of eliminating susceptibility to measles in the general population. Periodic follow-up SIAs then target all children born since the last SIA. Follow-up SIAs generally are conducted nationwide every 2–4 years and target children aged 9–59 months; their goal is to eliminate any measles susceptibility that has developed in recent birth cohorts and to protect children who did not respond to the first measles vaccination.
Data available at http://www.who.int/immunization/monitoring_surveillance/data/en.
Values >100% indicate that the intervention reached more persons than the estimated target population.